Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transaminases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    480 result(s) found for: Transaminases. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-002455-41 Sponsor Protocol Number: Start Date*: 2006-02-15
    Sponsor Name:Karolinska Institutet
    Full Title: Clinical, morphological and biochemical effects of antioxidant treatment of patients with chronic hepatitis C.
    Medical condition: Chronic hepatitis C with moderate to severe liver damage. The patients should not be suitable for standard medical treatment or refuse standard medical treatment for personal reasons.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002328-10 Sponsor Protocol Number: TIGEM1-MPSVI Start Date*: 2018-10-29
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.
    Medical condition: The clinical trial will be conducted on patients with Mucopolysaccharidosis Type VI. MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal d...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005730-11 Sponsor Protocol Number: K419 Start Date*: 2015-02-11
    Sponsor Name:KRANKENHAUS SALEM DER EVANG. STADTMISSION HEIDELBERG GGMBH
    Full Title: Effect of Clomethiazole (Distraneurin®) on CYP2E1 Activity, transaminases, Liver fat content, and liver stiffness during Alcohol Detoxification – a pilot Study
    Medical condition: Alcoholic liver disease in patients hospitalised for alcohol detoxification.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001323-64 Sponsor Protocol Number: 7/2008/O/Sper Start Date*: 2008-03-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: PHASE III DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY ON THE EFFICACY OF URSODEOXYCHOLIC ACID FOR THE TREATMENT OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY
    Medical condition: INTRAHEPATIC CHOLESTASIS OF PREGNANCY
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049055 Cholestasis of pregnancy LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004710-33 Sponsor Protocol Number: CAMEL 02 Start Date*: 2006-02-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PTK787 IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA
    Medical condition: Metastatic cutaneous melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002045-36 Sponsor Protocol Number: Start Date*: 2016-11-17
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Lifestyle induced weight loss and Liraglutide in the treatment of non-alcoholic steatohepatitis (NASH)
    Medical condition: Non-alcoholic steatohepatitis (NASH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001027-11 Sponsor Protocol Number: AS07/1104-001 Start Date*: 2005-06-03
    Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust
    Full Title: Diabetes in the Very Elderly Trial
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005116-12 Sponsor Protocol Number: CRAD001C2428 Start Date*: 2008-03-20
    Sponsor Name:Technical University of Munich
    Full Title: Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy New ...
    Medical condition: Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the furthe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006782-83 Sponsor Protocol Number: EC08/00230 Start Date*: 2013-09-24
    Sponsor Name:Hospital Universitario Virgen de las Nieves
    Full Title: Prevention MODS by modulating the inflammatory response through melatonin administration in surgical patients with severe sepsis.
    Medical condition: Septic patients of abdominal surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000178-31 Sponsor Protocol Number: TREATMENT-patients Start Date*: 2018-05-23
    Sponsor Name:Fundación para la Investigación e Innovación Biosanitaria de Asturias (FINBA)
    Full Title: Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001419-21 Sponsor Protocol Number: TPVAHC2012 Start Date*: 2013-08-15
    Sponsor Name:Universitätsklinikum Bonn
    Full Title: An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti...
    Medical condition: Acute Hepatitis C in HIV co-infection
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003369-24 Sponsor Protocol Number: ILIT-3L Start Date*: 2017-01-03
    Sponsor Name:Allergy Centre
    Full Title: Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and birch allergen or plac...
    Medical condition: Allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004726-28 Sponsor Protocol Number: ILIT2Linköping-Jönköping Start Date*: 2014-01-10
    Sponsor Name:Allergy Centre
    Full Title: Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and/or birch allergen one ...
    Medical condition: Allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004011-44 Sponsor Protocol Number: UofATURRIFIC Start Date*: 2020-05-20
    Sponsor Name:The University of Adelaide
    Full Title: A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruri...
    Medical condition: Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main symptom of this is itching. Ursodeoxycholic acid is routinely used to treat cholestasis but is not...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Ongoing) GB (GB - no longer in EU/EEA) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003381-33 Sponsor Protocol Number: EMR-62202-717 Start Date*: 2007-08-30
    Sponsor Name:Institute of Oncology Ljubljana
    Full Title: Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.
    Medical condition: Inoperable squamous cell carcinoma of the head and neck.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004328-35 Sponsor Protocol Number: 1006 Start Date*: 2007-01-29
    Sponsor Name:ARCAGY
    Full Title: Etude de phase II de l'association CISPLATINE TOPOTECAN et CETUXIMAB chez les patientes atteintes d'un cancer épithelial du col de l'uterus avancé ou en rechute.
    Medical condition: cervix carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005696-18 Sponsor Protocol Number: IPR/14 Start Date*: 2007-12-29
    Sponsor Name:MOLMED
    Full Title: NGR008 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic hepatocellular carcinoma HCC previously treated with no more than on...
    Medical condition: Patients affected by advanced or metastatic hepatocellular carcinoma HCC previously treated with no more than one systemic therapeutic regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055110 Hepatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004491-10 Sponsor Protocol Number: CAC-001-01 Start Date*: 2011-10-06
    Sponsor Name:Asklepion Pharmaceuticals, LLC
    Full Title: An Open-Label, Single-Center, Nonrandomized Study to Compare the Therapeutic Efficacy of To Be Marketed (TBM) Cholic Acid Capsules with that of the Currently Used (CU) Formulation of Cholic Acid Ca...
    Medical condition: Patients with inborn errors of bile acid synthesis and metabolism
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10070882 Inborn error in primary bile acid synthesis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003311-19 Sponsor Protocol Number: AIH-MAB Start Date*: 2018-01-09
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximab AIH-MAB
    Medical condition: Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histol...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000172-16 Sponsor Protocol Number: MO20927 Start Date*: 2007-08-24
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia.
    Medical condition: CD20-positive B-cell chronic lymphocytic leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA